Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | LPO | P22079 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903263 | 0.94 | CCNE1 (0.46) | CCNE1CDK2LPOF10L3MBTL1 | |
| SCHEMBL3532209 | 0.91 | — | — | |
| SCHEMBL19090065 | 0.86 | CCNE1 (0.35) | CCNE1CDK2LPOF10L3MBTL1 | |
| SCHEMBL19090066 | 0.86 | CCNE1 (0.35) | CCNE1CDK2LPOF10L3MBTL1 | |
| SCHEMBL1008868 | 0.86 | CCNE1 (0.35) | CCNE1CDK2LPOF10L3MBTL1 | |
| SCHEMBL27217132 | 0.84 | LPO (0.38) | CCNE1CDK2LPOF10KCNH2 | |
| SCHEMBL15431994 | 0.84 | F10 (0.40) | CCNE1CDK2LPOF10MEN1 | |
| SCHEMBL27217134 | 0.84 | LPO (0.38) | CCNE1CDK2LPOF10KCNH2 | |
| SCHEMBL15942427 | 0.82 | MEN1 (0.42) | LPOF10TNK2MEN1KMT2A | |
| SCHEMBL14960627 | 0.82 | ALDH1A1 (0.41) | LPOF10TNK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | CCNE1 285/4885CDK2 189/4885LPO 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.